Story perspectives

Novartis to Acquire Avidity for $12 Billion in 2026

10/26/2025

33 5

Summary

Story summary

Novartis AG will acquire Avidity Biosciences for about $12 billion, paying $72 per share, a 46% premium over Avidity's recent closing price.
The acquisition is expected to close in the first half of 2026, contingent on Avidity's business restructuring.
Novartis aims to strengthen its drug pipeline and has made multiple acquisitions in 2023, including Tourmaline Bio for $1.4 billion and Regulus Therapeutics for up to $1.7 billion.
Novartis also received FDA approval for a new treatment for chronic spontaneous urticaria, which could benefit 1.7 million U.S. patients.

1 of 1

Story summary

Novartis AG will acquire Avidity Biosciences for about $12 billion, paying $72 per share, a 46% premium over Avidity's recent closing price.
The acquisition is expected to close in the first half of 2026, contingent on Avidity's business restructuring.
Novartis aims to strengthen its drug pipeline and has made multiple acquisitions in 2023, including Tourmaline Bio for $1.4 billion and Regulus Therapeutics for up to $1.7 billion.
Novartis also received FDA approval for a new treatment for chronic spontaneous urticaria, which could benefit 1.7 million U.S. patients.